Assessing skin hydration in patients with sickle cell disease
Official title: Cutaneous Hydration Assessment in Sickle Cell Disease
Run by University of Pittsburgh · NCT05210114 · Data updated 2026-11-12
This study is testing a new skin sensor to see if it can help people with sickle cell disease manage their hydration better, especially during painful episodes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Status | Recruiting |
| Started | January 21, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | November 12, 2025 |
| Trial ID | NCT05210114 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 12 and older diagnosed with sickle cell disease.
✕Probably not a fit
Patients under 12 years old or those receiving experimental therapies in other clinical trials may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to validate the accuracy of a cutaneous hydration sensor for assessing hydration status in patients with sickle cell disease (SCD). The sensor will be evaluated for its feasibility as a point-of-care device to guide hydration therapy, particularly during vaso-occlusive episodes (VOE). Participants will have their skin hydration measured at baseline and after fluid resuscitation therapy, with blood and urine samples collected for comparison with laboratory biomarkers. The goal is to improve hydration management and prevent complications associated with improper fluid administration.
Why it matters
Potential benefit: If successful, this study could lead to better hydration management in patients with sickle cell disease, potentially reducing hospitalizations and improving patient outcomes.
How similar studies have gone: While the use of hydration sensors is emerging, this specific approach to hydration assessment in sickle cell disease is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Sickle Cell Disease (genotypes SS, SC, Sß-thalassemia, SD, SOArab) * Participants must be ≥12-years old * Participants that provide legally effective consent to all study procedures Exclusion Criteria: * Participants under 12-years old * Participants being treated with experimental therapies in clinical trials
Where it's running
-
UPMC Sickle Cell Clinic
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Enrico Novelli, MD — University of Pittsburgh
- Study coordinator: Enrico Novelli, MD
- Email: noveex@upmc.edu
- Phone: 412-916-3416
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cerebrovascular Reactivity Testing with HD-DOT in Sickle Cell Patients
This study tests whether high-density diffuse optical tomography can measure brain blood flow and oxygen use in people with sickle cell disease, to see how these signals relate to stroke risk.
-
Adapting and testing PEN-Plus in Zambian primary care
Aiming to see if the PEN-Plus package can be adapted and used in two Zambian hospitals to better manage chronic diseases like heart disease, diabetes, hypertension, and sickle cell in primary care.
-
Newborn Sickle Cell Screening in Mozambique
We’re testing a three-part plan to help babies in Mozambique get diagnosed early for sickle cell disease and start care quickly.
-
Optimizing Hydroxyurea in Children with Sickle Cell in Africa
This study tests whether raising hydroxyurea to a maximum tolerated dose is safe and beneficial for Ugandan children with sickle cell anemia already taking a fixed daily dose.
-
Hematopoietic stem cell editing to treat sickle cell disease
This study tests whether a patient’s own blood stem cells can be edited to remove the sickle cell triggering gene and then returned to the patient.
-
Virtual reality options to help with VOC pain in adults with SCD
This study tests whether headset-based virtual reality can help reduce pain for adults with sickle cell disease during vaso-occlusive crises treated in an infusion center.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.